细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体

Polyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)

CD274; PDCD1LG1; B7-H; B7H1; PD-L1; PDCD1L1; PDCD1-LG1; Programed Death Ligand 1

  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 产品包装(模拟)
  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 产品包装(模拟)
  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 DAB staining on IHC-P; Samples: Mouse Liver Tissue; Primary Ab: 10µg/ml Rabbit Anti-Mouse PDCD1LG1
  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 DAB staining on IHC-P;
    Samples: Mouse Testis Tissue;
    Primary Ab: 10µg/ml Rabbit Anti-Mouse PDCD1LG1 Antibody
    Second Ab: 2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 DAB staining on IHC-P;
    Samples: Mouse Heart Tissue;
    Primary Ab: 10µg/ml Rabbit Anti-Mouse PDCD1LG1 Antibody
    Second Ab: 2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • PAA788Mu01.jpg Figure. Western Blot; Sample: Recombinant PDCD1LG1, Mouse.
  • 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 Figure. Western Blot; Sample: Mouse Heart Tissue.
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

该抗体是针对PDL1的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别PDL1。

用法

Western blotting: 0.5-2µg/mL;1:500-2000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

储存

经常使用则4°C保存。-20°C保存不超过一年。避免反复冻融。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

相关产品

编号 适用物种:Mus musculus (Mouse,小鼠) 应用(仅供研究使用,不用于临床诊断!)
RPA788Mu01 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA788Mu02 细胞程序性死亡蛋白1配体1(PDL1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
PAA788Mu01 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 WB; IHC; ICC; IP.
PAA788Mu02 细胞程序性死亡蛋白1配体1(PDL1)多克隆抗体 WB; IHC; ICC; IP.
SEA788Mu 细胞程序性死亡蛋白1配体1(PDL1)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.

参考文献

杂志 参考文献
Chinese Journal of Cancer Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications [NCBI: PMC3937742]
Leukemia.? High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. [Pubmed:24732592]
Diabetes?Metab Res Rev. PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile [Pubmed:24816853]
Lancet Haematol Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study [PubMed: 26686046]
Eur J Cancer.  High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. [Pubmed:27039170]
Journal of Cancer Research and Clinical Oncology Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer [article:10.1007]
Journal of Hematology & Oncology PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma [pubmed:27737703]
Lung Cancer. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. [pubmed:28212990]
Oncotarget Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy. [pubmed:27780932]
Oncotarget High post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK/T cell lymphoma patients. [pubmed:27105512]
Oncotarget.  Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma [pubmed:27566569]
Cancer Immunol Immunother. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. [pubmed:28349165]
Leukemia Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients [leu2016385a]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. [pubmed:28207525]
Allergology International  Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients [pubmed:27617656]
Medicine Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy [PMC5319514]
American Journal of Respiratory and Critical Care Medicine Soluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM) [Pdf:10.1164]
Clinical Lung Cancer Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer [Pubmed:29859759]
Journal of Rheumatology Increased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis [Pubmed:29419471]
Translational Oncology High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [Pubmed:29698935]
留言咨询